TriMark Publications Online
Companion Biomarkers in Drug Development
Keywords: forecast, size, share, trends, industry, outlook, market, report


Full Report Price: $3,400.00
Delivery: Immediate Online Access
Publication Date: 01-APR-09
Pages: 320
Format: PDF Document  PDF Electronic Document
Add to Cart image


Report Description



View Sample PDF


The term "companion biomarker" means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played an important role in diagnostic medicine as evidenced by the intense use of specific clinical laboratory tests in the diagnosis of disease. Biomarkers can be used in five very distinct ways in drug development: 1) companion biomarkers can be correlated with biological events during drug development in order to validate drug targets or to predict drug response; 2) biomarkers can be used as companion diagnostics in drug development to characterize patient populations in order to better understand the extent to which new drugs reach intended therapeutic targets can alter proposed therapeutic pathways and achieve successful clinical outcomes; 3) biomarkers can be used to stratify patient populations for drug response in primary prevention or disease-modification studies, particularly in specific clinical areas such as neuron degeneration and cancer; 4) clinically useful biomarkers are becoming increasingly useful to make proper therapeutic decisions regarding candidate drugs; and 5) clinically useful biomarkers are becoming increasingly required by the FDA and other outside authorities to make proper regulatory decisions regarding candidate drugs. This TriMark Publications report describes new biomarker technology platforms developed for the analyses of drug targets that are connected to the effectiveness of therapeutic agents in a clinical setting. The emphasis is on those companies that are actively developing and marketing new companion diagnostic tests for performing biomarker tests during drug development, as opposed to the more routine and clinically accepted companion markers that are manufactured and marketed by large diagnostic companies for routine clinical use.


 

TriMark Research Products

Browse TriMark research reports & database tables:

Biotechnology
Diagnostics
Pharmaceutical
Medical Devices
Database Tables

About TriMark Publications

TriMark Publications is a Global Leader in Biotechnology and Healthcare Research, Advisory Services and Publishers of In-Depth Market Reasearch In Healthcare.

Home  Browse  Search  E-mail  Content Map
TriMark Publications Online, P.O. Box 465, Radio City Station, New York NY 10101